Oraya Therapeutics' INTREPID Study Published in Ophthalmology, the Official Journal of the American Academy of Ophthalmology
4/18/2013 8:57:48 AM
More...
|
New Therapy for Wet AMD Introduced in Switzerland by Oraya Therapeutics and EyeRAD
4/4/2013 12:03:15 PM
More...
|
Oraya Therapeutics's Successful INTREPID Study Outcomes Presented at EURETINA 2012 Congress
9/21/2012 9:40:33 AM
More...
|
Oraya Therapeutics Achieves Successful INTREPID Study Outcomes with a Non-Invasive Radiation Therapy for Wet AMD
5/3/2012 10:34:01 AM
More...
|
Oraya Therapeutics Completes Enrollment in Pioneering Sham-Controlled Study of Radiation Therapy for Wet AMD
5/18/2011 10:20:13 AM
More...
|
Oraya Therapeutics Granted European CE Mark for the IRayTM Stereotactic Radiotherapy System
4/7/2010 1:14:05 PM
More...
|
Oraya Therapeutics Initiates First Ever Sham-Controlled Study of Radiation Therapy for Wet AMD
1/5/2010 10:03:13 AM
More...
|
Oraya Therapeutics Names Jim Taylor as President and Chief Executive Officer
8/4/2009 11:56:13 AM
More...
|
Oraya Therapeutics Raises $42 Million in Series C Financing
7/20/2009 7:59:46 AM
More...
|